Javascript must be enabled to continue!
Design of an Affibody-Based Recognition Strategy for Human Epidermal Growth Factor Receptor 2 (HER2) Detection by Electrochemical Biosensors
View through CrossRef
In this study, we have designed and realized three simple electrochemical bioassays for the detection of the human epidermal growth factor receptor 2 (HER2) cancer biomarker using magnetic beads coupling screen-printed arrays. The different approaches were based on a sandwich format in which affibody (Af) or antibody (Ab) molecules were coupled respectively to streptavidin or protein A-modified magnetic beads. The bioreceptor-modified beads were used to capture the HER2 protein from the sample and sandwich assay was performed by adding the labeled secondary affibody or the antibody. An enzyme-amplified detection scheme based on the coupling of secondary biotinylated bioreceptor with streptavidin-alkaline phosphatase enzyme conjugate was then applied. The enzyme catalyzed the hydrolysis of the electro-inactive 1-naphthyl-phosphate to the electro-active 1-naphthol, which was detected by means of differential pulse voltammetry (DPV). Each developed assay has been studied and optimized. Furthermore, a thorough comparison of the analytical performances of developed assays was performed. Finally, preliminary experiments using serum samples spiked with HER2 protein were also carried out.
Title: Design of an Affibody-Based Recognition Strategy for Human Epidermal Growth Factor Receptor 2 (HER2) Detection by Electrochemical Biosensors
Description:
In this study, we have designed and realized three simple electrochemical bioassays for the detection of the human epidermal growth factor receptor 2 (HER2) cancer biomarker using magnetic beads coupling screen-printed arrays.
The different approaches were based on a sandwich format in which affibody (Af) or antibody (Ab) molecules were coupled respectively to streptavidin or protein A-modified magnetic beads.
The bioreceptor-modified beads were used to capture the HER2 protein from the sample and sandwich assay was performed by adding the labeled secondary affibody or the antibody.
An enzyme-amplified detection scheme based on the coupling of secondary biotinylated bioreceptor with streptavidin-alkaline phosphatase enzyme conjugate was then applied.
The enzyme catalyzed the hydrolysis of the electro-inactive 1-naphthyl-phosphate to the electro-active 1-naphthol, which was detected by means of differential pulse voltammetry (DPV).
Each developed assay has been studied and optimized.
Furthermore, a thorough comparison of the analytical performances of developed assays was performed.
Finally, preliminary experiments using serum samples spiked with HER2 protein were also carried out.
Related Results
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract P4-13-22: Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
Abstract
Background: A considerable proportion of patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) present with elevated serum levels of the ...
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract P4-15-07: HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemot
Abstract
Background: ASCO/CAP guidelines for the determination of HER2 amplification have recently been revised in an attempt to clarify which patients will benefit ...
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
HER2 expression dynamics and prognostic significance in the treatment of gastric cancer.
4025
Background:
The human epidermal growth factor receptor 2 (HER2) expression undergoes changes during the treatment of gastric canc...
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
HER2-positive Apocrine Carcinoma of the Breast: A population-based Analysis of Treatment and Outcome
Abstract
Aims
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+ APO (HER2...
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract P3-09-02: The HER2 –positive subtypes by stage and race/ethnicity
Abstract
HER2-positivity is often associated with poor survival. The purpose of this study is to determine if there are differences in mortality among the HER-positi...
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract P4-04-05: circHEACA promotes anti-HER2 drug resistance by HEACA-GRB7/AKT axis in HER2+ breast cancer patients
Abstract
Background: Some HER2-positive (HER2+) breast cancer patient are resistant to anti-HER2 therapy, and the potential reasons of anti-HER2 drug resistance rema...
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer.
e13024
Background:
Breast cancer is the second leading cause of cancer-related mortality among US women, with metastatic breast cancer...
Abstract P2-11-12: Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer
Abstract P2-11-12: Novel protocol combining metronomic nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer
Abstract
Background. Natural killer (NK) cells are an important effector cell type for adoptive cancer immunotherapy. Phase 1 clinical trials in patients with advanc...

